Skip to main content
Clinical Trials/NCT03699930
NCT03699930
Completed
Not Applicable

Impact of Neuromodulation on Language Impairments in Stroke Patients: a Multimodal Double-blind Randomized Controlled Study

Casa Colina Hospital and Centers for Healthcare1 site in 1 country24 target enrollmentJanuary 1, 2018
ConditionsStrokeAphasia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Casa Colina Hospital and Centers for Healthcare
Enrollment
24
Locations
1
Primary Endpoint
Change in Western Aphasia Battery-Revised scores
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Up to 40% of stroke survivors suffer from aphasia, making recovery of language abilities a top priority in stroke rehabilitation. Conventional speech and language therapy may have limited effectiveness. Leveraging multimodal data (behavioral, neuroimaging, and genetics), this study aims to 1) evaluate the efficacy of combining tDCS with speech therapy, 2) examine neural changes associated with recovery, 3) identify factors influencing response to treatment.

Detailed Description

Approximately one million people in the United States are living with aphasia, an acquired neurological disorder affecting the ability to use and/or understand language. This communication impairment affects up to 40% of stroke patients. Stroke victims usually prioritize speaking, writing, and walking as the three most important rehabilitation goals, two of these goals therefore involving communication. Conventional speech therapy strategies have nevertheless limited effectiveness in post-stroke aphasia. Indeed, approximately half of those affected will remain in this state despite intensive speech therapy. Effective novel treatment is therefore warranted to improve recovery in these patients. Recent evidence suggests that transcranial direct current stimulation (tDCS), a non-invasive, low-cost neuromodulation technique, applied in conjunction with speech therapy may be more effective in promoting language recovery than behavioral intervention alone. A double-blind quasi-randomized controlled study will be carried out in chronic post-stroke aphasics. Participants will be assigned to either the tDCS group or to the sham (placebo) group and will receive 20 minutes of concurrent speech and language therapy by a trained speech therapist over five consecutive days. Behavioral, EEG, and MRI data will be acquired within one week before and after intervention. Genetic samples will be collected once. Secondary behavioral outcome measures will be performed again 3 months following tDCS/sham intervention to assess long-term benefits.

Registry
clinicaltrials.gov
Start Date
January 1, 2018
End Date
January 1, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amy Zheng

Research Scientist

Casa Colina Hospital and Centers for Healthcare

Eligibility Criteria

Inclusion Criteria

  • Between ages 18-85
  • At least 12 months post stroke
  • Diagnosed with aphasia due to ischemic or hemorrhagic stroke
  • English speaking
  • Right handed prior to stroke

Exclusion Criteria

  • Nonverbal
  • Other neurological diseases/disorders
  • Not MRI-compatible (e.g. claustrophobia, metal implants in the head)

Outcomes

Primary Outcomes

Change in Western Aphasia Battery-Revised scores

Time Frame: At baseline and at week 3

WAB-R is an instrument for assessing the language function of adults with suspected neurological disorders as a result of a stroke.

Secondary Outcomes

  • Change in Magnetic Resonance Imaging (MRI)(At baseline and at week 3)
  • Change in Test of Nonverbal Intelligence (TONI-4)(At baseline and at week 3)
  • Change in Communication Outcomes after Stroke (COAST)(At baseline, at week 3, and at week 17)
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS)(At baseline, at week 3, and at week 17)
  • Change in resting state Electroencephalograph (EEG) signals(At baseline and at week 3)
  • Change in Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39)(At baseline, at week 3, and at week 17)

Study Sites (1)

Loading locations...

Similar Trials